5.23
Drugs Acting on Autonomic Ganglia: Stimulants
View the full transcript and gain access to JoVE Core videos
Q1: What are ganglionic stimulants and how do they work?
Ganglionic stimulants are agents that specifically activate nicotinic receptors (NN receptors) in autonomic ganglia. Being lipid soluble, they are readily absorbed through mucosal membranes. These drugs fall into two categories: nicotine mimetics like lobeline and tetramethylammonium, which act rapidly and are blocked by nicotinic antagonists, and muscarinic receptor agonists like muscarine, which act more slowly and are blocked by atropine-like agents.
Q2: How do ganglionic stimulants affect the cardiovascular system?
Ganglionic stimulants stimulate the adrenal medulla to release adrenaline, causing sympathetic stimulation and increased heart rate (tachycardia), which elevates blood pressure. Nicotine exhibits a biphasic effect on the adrenal medulla: small doses trigger catecholamine release, while large doses prevent it. This cardiovascular stimulation results from the drug's action on autonomic ganglia and direct effects on the adrenal gland.
Q3: What central nervous system effects occur with different doses of ganglionic stimulants?
Ganglionic stimulants produce dose-dependent CNS effects. At lower doses, they exhibit analgesic properties. Higher doses induce tremors and muscle weakness. Toxic doses can cause convulsions. These agents directly affect the medulla oblongata, leading to respiratory depression, diaphragm and intercostal muscle paralysis, and potentially labored breathing or respiratory failure in severe cases.
Q4: How are ganglionic stimulants metabolized and eliminated from the body?
Ganglionic stimulants undergo primary metabolism in the liver, with partial metabolism occurring in the lungs and kidneys. The kidneys are responsible for eliminating nicotine and its metabolites from the body. This hepatic metabolism and renal elimination pathway is important for understanding drug clearance and potential accumulation with repeated dosing.
Q5: What gastrointestinal and respiratory effects do ganglionic stimulants cause?
Ganglionic stimulants enhance gut tone and motility through parasympathetic cholinergic and ganglionic activation. Initially, bronchial and salivary secretions increase, followed by inhibition. These drugs trigger the chemoreceptor trigger zone (CTZ) in the brain, inducing vomiting. Adverse gastrointestinal effects include salivation, abdominal pain, and diarrhea.
Q6: What adverse effects and tolerance issues are associated with ganglionic stimulants?
Common adverse effects include dizziness, tremors, headache, mental confusion, weakness, and blood sugar irregularities. Chronic exposure to ganglionic stimulants increases nicotinic receptor density, contributing to dependence and tolerance development. Withdrawal symptoms may occur upon discontinuation. Severe toxicity can cause convulsions, respiratory failure, and potentially death.
Q7: What is the clinical use of nicotine as a ganglionic stimulant?
In clinical practice, nicotine is indicated for short-term replacement therapy in individuals abstaining from tobacco. Nicotine, an alkaloid ganglionic stimulant, affects heart rate by stimulating sympathetic or paralyzing parasympathetic ganglia. Its therapeutic application focuses on managing nicotine dependence during smoking cessation, though careful dosing is essential to avoid adverse effects from CNS stimulation or cardiovascular changes.